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Abstract
Background: Murine retroviral vectors have been used in several hundred gene therapy clinical trials, but
have fallen out of favor for a number of reasons. One issue is that gene expression from viral or internal
promoters is highly variable and essentially unregulated. Moreover, with retroviral vectors, gene
expression is usually silenced over time. Mammalian genes, in contrast, are characterized by highly
regulated, precise levels of expression in both a temporal and a cell-specific manner. To ascertain if
recapitulation of endogenous adenosine deaminase (ADA) expression can be achieved in a vector
construct we created a new series of Moloney murine leukemia virus (MuLV) based retroviral vector that
carry human regulatory elements including combinations of the ADA promoter, the ADA locus control
region (LCR), ADA introns and human polyadenylation sequences in a self-inactivating vector backbone.
Methods: A MuLV-based retroviral vector with a self-inactivating (SIN) backbone, the phosphoglycerate
kinase promoter (PGK) and the enhanced green fluorescent protein (eGFP), as a reporter gene, was
generated. Subsequent vectors were constructed from this basic vector by deletion or addition of certain
elements. The added elements that were assessed are the human ADA promoter, human ADA locus
control region (LCR), introns 7, 8, and 11 from the human ADA gene, and human growth hormone
polyadenylation signal. Retroviral vector particles were produced by transient three-plasmid transfection
of 293T cells. Retroviral vectors encoding eGFP were titered by transducing 293A cells, and then the
proportion of GFP-positive cells was determined using fluorescence-activated cell sorting (FACS). Non T-
cell and T-cell lines were transduced at a multiplicity of infection (MOI) of 0.1 and the yield of eGFP
transgene expression was evaluated by FACS analysis using mean fluorescent intensity (MFI) detection.
Results: Vectors that contained the ADA LCR were preferentially expressed in T-cell lines. Further
improvements in T-cell specific gene expression were observed with the incorporation of additional cis-
regulatory elements, such as a human polyadenylation signal and intron 7 from the human ADA gene.
Conclusion: These studies suggest that the combination of an authentically regulated ADA gene in a
murine retroviral vector, together with additional locus-specific regulatory refinements, will yield a vector
with a safer profile and greater efficacy in terms of high-level, therapeutic, regulated gene expression for
the treatment of ADA-deficient severe combined immunodeficiency.
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Background
Severe combined immunodeficiency (SCID) is a pediatric
hereditary disorder which affects an individual's T-cells,
leaving the individual with practically no immune system.
Traditional methods of treatment for SCID include bone
marrow transplant or enzyme replacement therapy [1].
These methods are painful, expensive and have a high risk
of morbidity and mortality [2-4]. However, gene therapy
can offer another potential treatment for SCID. Gene ther-
apy is a very promising treatment for adenosine deami-
nase severe combined immunodeficiency (ADA-SCID) [5-
7], not only because the nature of the disorder makes the
patient less likely to reject the vector, but also because it is
a well characterized monogenic disorder. Despite
advances in the field during the past 30 years, there are
still several obstacles to overcome.
Traditional murine retroviral vector designs utilizing viral
promoter elements exhibit highly variable and often
reduced expression over time, due to silencing, which usu-
ally leads to an insufficient therapeutic effect [8-10]. Fur-
thermore, viral promoter elements are constitutively
active and may result in unregulated, unsafe, and variable
levels of transgene expression. Such unregulated expres-
sion may be one reason for the development of a leuke-
mic-like syndrome in five patients recently treated for X-
linked SCID (X-SCID) [11-13].
Mammalian genes, in contrast, exhibit highly regulated,
stable and precise levels of expression in both a temporal
and a cell-type specific manner. Recent studies have begun
to elucidate the mechanisms by which large-scale chroma-
tin architecture regulates the expression of individual
genes [14,15]. Many mammalian genes use extensive cis-
regulatory information, such as locus control regions
(LCR) and boundary elements, to achieve regulated and
cell-specific control of gene expression [16]. Therefore,
successful gene therapy of many genetic diseases may
require stringent and appropriate control of vector-intro-
duced gene expression. The use of LCRs or related mam-
malian gene regulatory elements will likely be
advantageous, or even essential, for the achievement of
safe, consistent, high-level expression of a therapeutic
transgene from the context of a gene therapy vector in
clinical trials [17].
There has been considerable progress in the development
of integrating vectors containing elements of the human
β-globin LCR for the treatment of sickle cell anemia and
β-thalassemia [18-23]. However, it has previously not
been possible to produce high titer murine retroviral vec-
tors containing a human LCR. We report here for the first
time the incorporation of key cis-regulatory sequences
from the human ADA gene [24] into a retroviral vector for
the treatment of ADA-SCID (Additional file 1). These vec-
tors contain the human ADA LCR and the human ADA
promoter within a self-inactivating (SIN) Moloney
murine leukemia virus (MuLV) vector backbone. High tit-
ers and T-cell specificity of reporter gene expression were
observed. A subset of these vectors contains the human
growth hormone polyadenylation signal while further
subsets contain introns from the ADA gene. These altera-
tions in vector design have yielded construct-specific
increases in T-cell specific gene expression.
These novel vectors demonstrate transcriptional targeting
of T-cells and expression of the enhanced green fluores-
cent protein (eGFP) reporter gene in a manner similar to
endogenous ADA gene expression. We believe that vectors
capable of authentic gene-specific regulation will prove to
be a safer and more effective alternative to previous vec-
tors for the treatment of ADA-SCID and other genetic dis-
eases. The vector constructs presented herein provide a
model for a new generation of retroviral vectors capable of
cell-type specific gene expression.
Materials and methods
Retroviral vector constructions
The MuLV based WTPG (WT = wild type U3; P = phos-
phoglycerate kinase promoter; G = eGFP reporter gene)
vector was constructed by combining the following frag-
ments into the Bluescript KS vector (Stratagene, La Jolla,
CA). The 5' LTR and packaging sequences were cloned
from pHIT 112 [25] and the 3' LTR and polypurine tract
was cloned from pG1 [26]. The PGK promoter was iso-
lated from PGK-Pic20H (from Dr. French Anderson's lab-
oratory, University of Southern California, Dr. Bret Ball's
PhD Thesis) by digestion with BglII (blunt) and EcoRI and
ligated into BamHI (blunt) and EcoRI digested peGFP-N1
(Clontech, Palo Alto, CA). Subsequently the PGK-eGFP
gene cassette was isolated by HindIII  and NotI  (blunt)
digestion and cloned into HindIII and EcoRI (blunt) sites
of WTPG.
SIN 80 is a SIN backbone, cloned from WTPG, which has a
334 bps deletion in U3, leaving 35 bps on the 5' end and 80
bps on the 3' end (deleting all the enhancer and the majority
of the CAT box). After amplification by polymerase chain
reaction (PCR) with primers 5'GTACCGCTAGC
GATATCAGTTCGCTTCTCGC3' and 5'GTAATACGACT-
CACT ATAGGG3', the fragment was digested with NheI and
NotI and inserted into the corresponding sites in the short-
ened WTPG vector backbone. The BamHI-XbaI eGFP frag-
ment (peGFP-N1) was inserted into the BamHI and XbaI
sites to form the intermediate construct SG (S = SIN; G =
eGFP reporter gene). The XbaI/SalI fragment of ADA LCR was
digested from the pADA CAT 4/12 vector (the kind gift of
Bruce Aronow, University of Cincinnati) [27] and cloned
into the XbaI/SalI site of the SG plasmid to form the interme-
diate construct SGL (L = human ADA LCR). The ADA pro-
moter was PCR amplified with primers
5'GAACGCTAGCGAGGCTTGCGATGCTCC3' and 5'GAAGenetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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CGCTAGCGCGCGCTCACTTTGGGCT3' and inserted into
the HindIII and AgeI restriction sites of SG and SGL plasmids
to construct SAG (A = human ADA promoter) and SAGL.
The PGK promoter was digested from PGK-Pic20H using the
HindIII and AgeI restriction enzymes and inserted into the
corresponding sites of SG and SGL to generate SPG and
SPGL vectors. SLAG and SiLAG (iL = inverted LCR) were con-
structed by ligation of the XbaI (blunt) fragment of the ADA
LCR into the HindIII (blunt) site of SAG. SAGiL was con-
structed from SAG and SAGL. The ADA LCR was isolated
from SAGL by digestion with XbaI (blunt) and HincII and
inserted into the HincII restriction site of SAG.
The next series of vectors constructed contained the ADA
promoter (A), eGFP (G), and human growth hormone
polyadenylation signal (H) as a cassette in the inverted
orientation to generate SHGAL construct. For this pur-
pose, the human growth hormone polyadenylation signal
was amplified by PCR from human genomic DNA with
primers
5'ATGACCTAGGGGATCCACCGGTTCTAGAGTTAACGT
GGCATCCCTGTGAC3' (5' to 3', BamHI, AgeI, XbaI, Hin-
cII, bold) and 5'GAACAAGCTTGCCA AGCAAGC
AACTCAA3' (HindIII, bold) and subsequently cloned
into the HindIII/BamHI sites of SLAG. The ADA promoter
was then introduced into the BamHI site and AgeI site
from the corresponding sites on SAG. The eGFP reporter
gene was cloned into the AgeI and XbaI restriction sites
from the corresponding sites on peGFP-N1.
Human ADA introns (I) 7, 8, and 11 were PCR amplified
from human genomic DNA. Primers were designed to
incorporate a 5' and 3' EcoRV site (bold) for each set of
introns 5'GAGATATCAGTAAAAGAGGTGAGGGCCTG3'
and 5'GAGATATCTCCACAGCCTGTAGAGAAGCA3' for
intron 7; 5'GAGATATCAGGAAAACATGCACTTCGAGG3'
and 5'GAGATATCGGCAGATCTGAAGAGCAGGT3' for
intron 8; 5'GAGATATCAGTAAAAGAGGTGAGGGCCTG3'
and 5'GAGATATCGGCAGATCTGGAAGAGCAGGT3' for
introns 7-8; and 5'GAGATATCTTCAGCCTCTGCAGGTA
GGTT3' and 5'GAGATATCTTCTGCCCTGCTCGTTGGTT3'
for intron 11. PCR products were digested with EcoRV
(blunt) and inserted into the XbaI site (blunt) of SHGAL
to form SHI7GAL, SHI8GAL, SHI78GAL, SHI11GAL and
into the AgeI site (blunt) to form SHGI7AL, SHGI8AL,
SHGI78AL and SHGI11AL.
Two additional plasmids with multiple cloning sites
(MCS), MCS-SHGA and MCS-SHGAL, were produced in
order to facilitate with the construction of SHGAiL,
SLHGA, and SiLHGA. In order to introduce multiple clon-
ing sites upstream to the human growth hormone polya-
denylation signal and downstream to the ADA promoter,
the forward PCR primer contained sites (5' to 3') SalI,
MluI, AsiSI, and NruI (bold) 5'GCGATGGTCGACACGCG
TGCGATCGCTCGCGATAGCTTGCCAAGCAAACAACT-
CAAATGTCC-3' and reverse PCR primer contained sites
(5' to 3') SalI, PmeI, PmlI, PacI, and AscI (bold)
5'GCATCCGTCGACGTTTAAACCACGTGTTAATTAAGGC
GCGCCCTCGAGGCTTGCGATGCTCCCGGGGTC3' were
used for HGA fragment amplification from SHGAL. The
HGA PCR product was digested with SalI and introduced
into the SalI digested SIN backbone fragment of SiLAG to
create MCS-SHGA. Primers 5'GAGTGCG-
GCGCGCCCACGT GTATCGATACTTAAGGCATGCAC
CACCATGCCCGGC3' (5' to 3', AscI, PmlI, ClaI, and AflII,
bold) and 5'GCTCGGTTTAAACTTAA TTAACACCG
GCGAAGCTTGGATCCATGCCACATAGCAAGGTGCTGG
GTCAC3' (5' to 3', PmeI, PacI, SrgAI, HindIII, and BamHI,
bold) were used to incorporate multi-cloning sites into
the 5' and 3' of ADA LCR. The PCR product of the ADA
LCR amplification was digested with AscI and PmeI and
ligated with the AscI/PmeI fragment of MCS-SHGA to cre-
ate MCS-SHGAL. The ADA LCR was isolated from MCS-
SHGAL by digestion with PacI and PmlI and cloned into
MCS-SHGA at the PacI /PmlI or AsiSI /NruI sites to create
SHGAiL and SiLHGA respectively. SLHGA was created via
isolation of the ADA LCR with AscI and PmeI then intro-
duced into MCS-SHGA digested with MluI  and  NruI.
SHGI7AiL, SLHGI7A, and SiLHGI7A were constructed by
the same ways as described above with a MCS-SHGI7A
and the PCR product of the ADA LCR amplification.
Cell lines and culture conditions
293T, 293A, NIH3T3, and HeLa (adherent cells, kindly
provided by Dr. Paula Cannon, University of Southern
California, Keck School of Medicine) [25,28,29] were cul-
tured in Dulbecco's Modified Eagle Medium (Mediatech,
Herndon, VA) supplemented with 10% fetal calf serum
(Hyclone, Logan, UT, or Gemini Bio-products, Wood-
land, CA). The adherent rat non T-cell line, XC was also
kindly provided by Dr. Paula Cannon [30] and cultured in
Minimal Essential Medium (Gibco BRL, Carlsbad CA).
Cells were passaged 1:5 every other day or as needed. The
non-adherent Molt-4 human T-cell line was kindly pro-
vided by Dr. Bruce Aronow (University of Cincinnati)
while the non-adherent EL-4 murine T-cell line was
obtained from the American Type Culture Collection
http://www.atcc.org. CEM, CEM-SS, Jurkat E6-1, and VB
non-adherent human T-cell lines were obtained from the
NIH AIDS Research and Reference Reagent Program
(Rockville MD). All T-cell lines were grown in RPMI 1640
(Mediatech, Herndon, VA) supplemented with 10% fetal
calf serum.
Production of virus containing cell culture supernatant and 
determination of viral titer
Retroviral vector particles were produced by transient
three-plasmid transfection of 293T cells by overnight cal-
cium phosphate treatment on 10 cm dishes seeded the
previous day to give a maximum of 70% confluence/plateGenetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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on the day of transfection [23,25,31]. For each transfec-
tion, 10-50 μg of vector plasmid, 10 μg of pol-gag (pCGP)
packaging plasmid [25], and 2 μg of vesicular stomatitis
virus G protein (pVSV-G) envelope plasmid [25] (both
from Dr. Paula Cannon, University of Southern Califor-
nia) were used. Twelve to sixteen hours after transfection,
cells were gently washed with PBS, warmed to 37°C, and
6 ml of fresh medium with 10 mM sodium butyrate was
added. After 8 hours of incubation, the medium was
replaced with 6 ml of fresh medium. Thirty-six hours after
transfection, supernatants containing viral particles were
harvested and passed through a 0.45-micron filter (Milli-
pore, Bedford, MA) to remove cells and cellular debris.
Polybrene was added to filtered vector supernatants to a
final concentration of 8 μg/ml, and then the vectors were
stored in aliquots at -80°C.
All retroviral vectors encoding eGFP were titered by trans-
ducing 293A cells, as described below, with serial dilu-
tions of the vectors preparations. 293A cells were plated
16 hours prior to transduction at a concentration of 3-5 ×
105 cells per well in 6-well plates. On the day of transduc-
tion, five serial 1:3 dilutions of thawed virus containing
supernatant were prepared; 1 ml of each dilution were
directly added to the cells and incubated at 37°C for 4 to
8 hours. After incubation, vector supernatants were
removed and fresh medium was added. Cells were cul-
tured for 2 to 3 days, then trypsinized, PBS washed, and
fixed with 4% paraformaldehyde (pH 7.2) before they
were analyzed for transgene expression by fluorescent-
activated cell sorting (FACS) [32] on the Beckman Coulter
Epic XL-MCL to enumerate the proportion of GFP-posi-
tive cells. In order to compensate for autofluorescence of
untransduced cells, two-dimensional FACS gating was
used. Titers were routinely determined from a volume of
vector preparation that yielded linear, dose dependent
transduction of target cells with a level not in excess of
20% [33]. The ranges of titers obtained from 2 to 24 inde-
pendent titrations for each vector are presented in Table 1.
Cell transduction and FACS analysis of eGFP expression
Adherent cells were plated 16 hours prior to transduction
at a concentration of 3-5 × 105 cells per well in 6-well
plates and non-adherent cells were plated the day of trans-
duction at a concentration of 1 × 106 cells per well in 6-
well plates. All cells were transduced at a multiplicity of
infection (MOI) of 0.1 infectious viral particles per cell
and incubated for two to three weeks to allow stabiliza-
tion of gene expression and to eliminate non-integrating
proviral remnants. After two to three weeks of culture,
adherent cells were treated as described above and non-
adherent cells were PBS washed and fixed with 4% para-
formaldehyde. For each sample, 200,000 events were ana-
lyzed by FACS to obtain the mean florescent intensity
(MFI) and the percentage of eGFP positive cells. Two to
eight independent experiments were performed in dupli-
cates; mean values with corresponding standard errors of
the mean were calculated unless indicates otherwise.
Results
Construction of Moloney MuLV SIN vectors containing the 
human ADA promoter LCR
Initially, we undertook to incorporate the human ADA
LCR, together with its natural ADA promoter, into the
MuLV retroviral vector backbone. The first series of vector
constructs were made with the LCR in various configura-
tions and orientations (Figure 1). WTPG is a standard
non-SIN MuLV retroviral vector in which the PGK pro-
moter is used to drive expression of the eGFP reporter
gene. SPG and SAG contain either the PGK promoter or
the ADA promoter within a SIN MuLV vector backbone
[34]. These vectors were used to establish the baseline
gene expression level of eGFP. SAGL is the experimental
vector incorporating the ADA LCR 3' to the ADA promoter
while SPGL assesses the ability of the LCR to affect expres-
sion from a heterologous promoter, PGK. These con-
structs demonstrated that the ADA LCR can be
successfully incorporated into retroviral vectors at reason-
ably high titers of 105-107 infectious virus particles/ml
(Table 1A).
The ADA LCR was also inserted into SAG 5' to the ADA
promoter in both the forward and reverse orientations,
forming SLAG and SiLAG (Figure 1). Classically, enhanc-
ers function in an orientation- and position-independent
manner, suggesting that the enhancer function of the LCR
should not be affected by an alteration in location or ori-
entation with respect to the target promoter [35]. How-
ever, some evidence has shown that LCRs may not always
be position- or orientation-independent [36]; SiLAG and
SAGiL test this property. Results, shown in Figure 2, sug-
gest that the ADA LCR is orientation-independent, in that
the LCR in the inverted direction within both SAGiL and
SiLAG does not substantially affect reporter gene expres-
Table 1: Comparison of virus titers of MuLV SIN vectors in 293T 
cells. 
A. B.
Vector Titer (cfu/ml) Vector Titer (cfu/ml)
WTPG 1.8-2.0 × 107 SHGAL 0.12-2.9 × 105
SPG 8.0 × 106 SHGAiL 0.4-1.5 × 106
SPGL 1.0 × 106 SLHGA 0.3-1.1 × 105
SAG 0.8-1.5 × 107 SiLHGA 3.5-7.3 × 104
SAGL 2.0-3.1 × 106 SHGI7AL 0.07-2.6 × 105
SAGiL 4.8 × 105 SHGI7AiL 0.4-2.1 × 106
SLAG 0.5-1.0 × 106 SLHGI7A 0.3-1.4 × 105
SiLAG 1.1-2.9 × 106 SiLHGI7A 0.4-1.5 × 105
The ranges of titers obtained from 2 to 24 independent titrations for 
each vector are presented.Genetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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sion in 293T or Jurkat cells, when compared to SAGL and
SLAG, respectively. Thus, the ADA LCR displays a property
of classical enhancers, as it functions in an orientation-
independent manner in the context of these retroviral vec-
tors.
However, there is a strong preference for the ADA LCR to
be positioned 5' to the ADA promoter, as seen in Figure 2,
where vectors containing the ADA LCR 5' to the ADA pro-
moter show highly enhanced, preferential gene expres-
sion in the Jurkat human T-cell line as compared to 293A
cells. Thus, the ADA LCR does appear to possess position-
dependence, which is orientation independent with
respect to the ADA promoter.
Vectors containing the ADA LCR demonstrate high-level 
gene expression in T-cell lines
One measure of LCR function is the ability to generate
expression in a cell-specific manner. In some cell types,
traditional retroviral vectors are known to express poorly
despite successful integration [9]. Such cells exhibit lower
relative titers due to this failure of expression [37]. A graph
of the MFI of various vectors transduced in Jurkat cells
demonstrates that ADA LCR containing vector, SiLAG
yields higher cell-specific expression levels in Jurkat cells
than the non-LCR counterparts, namely SAG and WTPG
(Figure 3A).
To further evaluate this effect, additional human T-cell
lines (Molt4, CEM, CEM-SS, and VB), the murine EL4 T-
cell line, and non-T-cell lines (HeLa, 293T, 3T3, and XC)
were used to assess the cell-type specific gene expression
for the vector SAG and the best performing vector thus far
in the Jurkat T-cell line, namely SLAG. When the ADA LCR
was included in the vector, enhancement of reporter gene
expression was observed in all T-cell lines tested, suggest-
ing that the ADA LCR is functioning to increase gene
expression in T-cell lines (Figure 3B). Incorporation of the
ADA LCR did not result in enhanced gene expression in
non-T-cell lines, but rather a slight reduction, (Figure 3C).
Thus, the ADA LCR is functioning in a cell-type specific
manner.
The incorporation of additional cis-regulatory elements, in 
combination with the ADA LCR, increases eGFP expression 
in T-cell lines
Previous studies have shown that successful lentiviral vec-
tors have been developed with the β-globin promoter,
gene and a polyadenylation signal placed in reverse orien-
tation to the vector element and the β-globin LCR in the
direct orientation 3' to these elements for increased stabil-
ity [18]. Therefore, a similar arrangement was used for our
studies; the ADA promoter, eGFP reporter gene, and
human growth hormone polyadenylation signal were
Proviral configuration of MuLV SIN vector constructs incor- porating the human ADA LCR Figure 1
Proviral configuration of MuLV SIN vector con-
structs incorporating the human ADA LCR. A series 
of eight vectors were constructed in order to test the func-
tionality of the human ADA LCR in the context of a retrovi-
ral vector. WTPG, SPG, and SAG are control vectors. SAGL 
contains the LCR 3' to the ADA promoter and eGFP gene 
while SAGiL has an inverted LCR in the same position. SPGL 
examines the ability of the LCR to function with the heterol-
ogous PGK promoter. SLAG contains the LCR 5' to the 
ADA promoter in the forward direction while SiLAG con-
tains the LCR inserted in the reverse orientation. WT = U3 
region is wild type; S = SIN vector with deletion in 3' U3; P = 
PGK promoter; G = eGFP reporter gene; A = human ADA 
promoter; L = human ADA LCR.
ADA LCRs function in an orientation-independent but posi- tion-dependent manner within a retroviral vector Figure 2
ADA LCRs function in an orientation-independent 
but position-dependent manner within a retroviral 
vector. 293A or Jurkat cells were transducted by different 
vectors (WTPG, SAG, SAGL, SAGiL, SLAG and SiLAG) 
expressing eGFP reporter gene at MOI of 0.1. The mean flo-
rescent intensity (MFI) of eGFP expression was evaluated 
using FACS 3 weeks post-transduction.Genetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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Vectors Containing the ADA LCR 5' to the ADA Promoter Show Cell Specific Enhanced Expression Figure 3
Vectors Containing the ADA LCR 5' to the ADA Promoter Show Cell Specific Enhanced Expression. A. 
Enhanced expression of eGFP under the SiLAG vector in Jurkat cells, a human T-cell line, as determined by FACS analysis. B. 
LCR-mediated enhancement of eGFP expression in both human and murine T-cell lines. C. The ADA LCR does not enhance 
expression of eGFP in non-T-cell lines. MFI of eGFP expression was measured by FACS and normalized to the MFI of SAG 
transduced cells.
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placed in reverse orientation within the vector. The LCR
was placed in the forward orientation adjacent to the pro-
moter to create a novel vector, named SHGAL (Figure 4A).
Given the inverse orientation of the LCR with respect to
the ADA promoter, the SHGAL vector is configured simi-
larly to the SiLAG vector, which showed preferentially
high reporter gene expression in T-cell lines.
The addition of the human growth hormone polyadenyla-
tion signal reduced the titer by approximately one log
compared to the non-LCR containing vector, SAG, but the
SHGAL vector was still able to maintain a relatively high
titer of 8.5 × 104 in 293A cells (Table 1A, 1B). Although
SHGAL displayed slightly reduced titer, the MFI in Jurkat
cells had an 11.8 and 2.7-fold enhancement over levels
observed in SAG and SiLAG, respectively. Enhanced gene
expression was also observed in other T-cell lines such as
CEM and Molt-4, however, expression levels remained
unchanged in the non T-cell line, 293A (Figure 4B). The
percentage of eGFP positive cells noticeably increased
with elemental changes made to SAG, SiLAG, and SHGAL
in both non-T-cell and T-cell lines (Figure 4C). However,
an enhancement of gene expression was observed only in
T-cell lines (Figure 4B). Thus, our studies revealed that the
use of an inverted gene expression cassette with a human
polyadenylation signal, placed in an inverted configura-
tion, similar to that used in other integrating vectors to
generate tissue-specific expression of the β-globin gene,
yields substantially increased levels of tissue-specific gene
expression.
The addition of intron 7 further increases eGFP expression 
in a cell-type specific manner
The inclusion of an intron within a retroviral vector has
been previously reported to facilitate processing of the
mRNA transcripts, thus resulting in enhanced transgene
expression [38]. In an attempt to further increase titer and
MFI, three introns (7, 8, and 11) and a pair of introns (7
and 8) from the human ADA gene were introduced into
the SHGAL vector. Small introns were chosen in light of
Additional cis-regulatory elements further improve vector gene expression Figure 4
Additional cis-regulatory elements further improve vector gene expression. A. SHGAL contains the human growth 
hormone polyadenylation signal (H) (pA in orange) 5' to the eGFP. 293A, Jurkat, Molt-4 and CEM cells were transduced by 
SAG, SiLAG or SHGAL vectors at MOI of 0.1. The MFI of eGFP expression (B) and the percentage of eGFP positive cells (C) 
were evaluated using FACS analysis.Genetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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the size limitations of a retroviral vector genome [39]. The
introns were inserted either 5' or 3' to the eGFP gene to
form the following vectors: SHI7GAL, SHI8GAL,
SHI7+8GAL and SHI11GAL; and SHGI7AL, SHGI8AL,
SHGI11AL, and SHGI7+8AL. Of theses vectors, only
SHGI7AL (Figure 5A) demonstrated improved expression
over the parental vector, SHGAL (data not shown). How-
ever, the insertion of intron 7 did not yield a significant
change in 293T-derived titer as compared to SHGAL
(Table 1B).
A comparison of the SHGI7AL versus the SHGAL vector in
various T-cell lines and in the non-T-cell line, 293A, is
shown in Figure 5B. The SHGI7AL vector yielded
enhanced gene expression in all the T-cell lines tested,
namely Jurkat, Molt-4 and CEM, as compared to SHGAL.
Even though the number of positive cells is highest in
293A cells (Figure 5C), the level of gene expression is not
enhanced in these non-T-cell line for SHGI7AL, as shown
in Figure 5B, thus demonstrating that the gene is being
expressed in a cell-type specific manner.
From prior studies, as well as the results of the present
study, we see that an LCR is not always position-inde-
pendent. Hence, several more constructs were created to
test this property and to discern if further improvements
could be made for titer and/or expression levels. The con-
structs generated were variations of vectors SHGAL and
SHGI7AL with the LCR either in the forward or reverse ori-
entation and located 3' to the polyadenylation signal or
with the LCR in the reverse orientation as compared with
SHGAL and SHGI7AL.
SHGAiL and SHGI7AiL, which have the LCR is in the
inverted orientation, produced titers that surpassed the
parent vectors, SHGAL and SHGI7AL, by one log (Table
1B). SLHGA, SiLHGA, SLHGI7A and SiLHGI7A, in which
the LCR was positioned 3' to the polyadenylation signal
Insertion of intron 7 of the ADA gene results in further enhancement of gene expression Figure 5
Insertion of intron 7 of the ADA gene results in further enhancement of gene expression. A. SHGI7AL contains 
intron 7 of the ADA gene in the inverted reverse orientation with respect to the vector elements. 293A, Jurkat, Molt-4 and 
CEM cells were transduced by SAG, SHGAL or SHGI7AL vectors at MO of 0.1. The MFI of eGFP expression (B) and the per-
centage of eGFP positive cells (C) were evaluated using FACS analysis.Genetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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(Figure 6A), all failed to show improvements in titers and,
in fact, yielded the poorest titers of all the vectors in the
second series (Table 1B). Vectors containing intron 7
showed gradual improvements in MFI over SHGAL,
except for SLHGI7A, but none of these vector configura-
tions was able to exceed the MFI of SHGI7AL (Figure 6B).
As was observed for all LCR-containing vectors to date,
there was no enhancement in gene expression in the non-
T-cell line, 293A.
Discussion
Previous clinical trials have faced obstacles to successful
gene therapy in three key areas: gene delivery, gene expres-
sion, and safety. The purpose of this study was to develop
a new generation of murine retroviral vectors in which the
viral regulatory signals are replaced with gene-specific
human regulatory sequences in order to generate safer and
more effective treatments for inherited immunodeficien-
cies. Many clinical trials have utilized retroviral vectors
because their efficiency of gene delivery and capacity for
integration into the host genome provide the greatest
potential for long-term correction of a disease. However,
there are a number of intrinsic problems and risks associ-
ated with using the traditional MuLV retroviral vector, as
discussed by Baum et al. [17]. Recent advances in our
understanding of cellular transcriptional regulation are
facilitating the development of vectors completely regu-
lated by human sequences which can generate appropri-
ate and authentic expression of a therapeutic gene.
Improvements in retroviral vector design are necessary to
incorporate human regulatory sequences without
adversely affecting gene transfer efficiency. Vectors with
incorporated sequences that correspond to specific endog-
enous regulatory elements should prove to be safer and
more effective than traditional retroviral vector designs
due to more authentic regulation, which should result in
less promiscuity and less variable expression.
The LCR from the ß-globin gene and its incorporation
into lentiviral vectors has been used as a model system by
a number of laboratories [18-23]. Recent work demon-
strated considerable success [18,19]. Earlier studies using
murine retroviral vectors and ß-globin elements encoun-
tered a number of problems including: 1) vector instabil-
ity, with a high frequency of deletions and
rearrangements, 2) inauthentic gene expression patterns,
and 3) low levels of gene expression often accompanied
by high levels of clonal variation and the silencing of
expression over time [40-42]. In light of these difficulties,
the successful use of lentiviral vectors for the treatment of
ß-globinopathies has been a significant advancement.
However, there are situations in which a lentiviral vector
may not be ideal for gene transfer. While lentiviral vectors
do exhibit a number of advantages over the traditional
murine retroviral vector, there are, nonetheless, signifi-
cant safety concerns about administering a lentivirus-
based vector to a human patient, particularly for the treat-
ment of a genetic disease in a child as opposed to the treat-
ment of HIV or cancer in an adult. Therefore, as the long-
term clinical effects of a lentiviral vector remain largely
unknown, the development of a safe and efficacious
murine retroviral vector could have a role in the treatment
of a number of genetic diseases.
The model disease for testing gene therapy treatments has
traditionally been SCID, caused either by ADA or γc chain
deficiencies [6,7,43,44]. These two genetic diseases are
ideal because the administration of gene-corrected cells
results in a positive selective advantage and preferential
survival of "normal" gene-corrected cells [43]. Develop-
ment of a leukemia-like syndrome in five patients follow-
ing successful treatment of SCID, however, has
demonstrated that unregulated gene expression is a
potential danger, particularly when coupled with vector
insertion adjacent to a potential proto-oncogene [11-
SHGI7AL show no improved expression with the LCR in var- ious positions and orientations Figure 6
SHGI7AL show no improved expression with the 
LCR in various positions and orientations. A. SHGI7AL 
contains intron 7 inserted 5' to the ADA promoter, while 
SHGI7AiL contains the LCR in the reverse orientation. 
SLHGA, SLHGI7A, SiLHGA and SiLHGI7A possess the LCR 
5' to the polyadenylation signal in both the forward and 
reverse direction respectively. These vectors were created 
to examine if the LCR functions independently of position 
and orientation. B. 293A, Jurkat, and Molt-4 cells were trans-
duced by SHGI7AL, SHGI7AiL, SLHGI7A or SiLHGI7A vec-
tors at MOI of 0.1. The MFI of eGFP expression was 
evaluated using FACS analysis.Genetic Vaccines and Therapy 2009, 7:13 http://www.gvt-journal.com/content/7/1/13
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13,45]. Even though this is a tragic unforeseen develop-
ment, two of the five children have been successfully
treated for leukemia while another child is currently
receiving treatment [12,13].
Our studies indicate that the addition of the 2.3 kb ADA
LCR placed within a SIN backbone is able to provide T-
cell-specific gene expression in a retroviral vector with
minimal effect on titer. This is observed in the SLAG and
SiLAG vector construct, which both exhibited improve-
ments in MFI by a 4.4-fold increase compared to SAG in
the T-cell line, Jurkat. This increase in gene expression also
was observed in other T-cell lines such as Molt-4 and
CEM. Moreover, the introduction of additional cis-regula-
tory sequences, such as a human polyadenylation signal
for the SHGAL vector or the introduction of both the
human polyadenylation signal and intron 7 from the
human ADA gene for the SHGi7AL vector further
improved T-cell specific transgene expression, but dis-
played some decrease in titers in 293T cells, as compared
to vectors containing only the LCR. The MFI of SHGAL
and SHGI7AL was increased over 11.8 and 16.1-fold,
respectively in Jurkat cells as compared to SAG. With the
LCR in the inverted orientation, as seen in SHGAiL or
SHGI7AiL, titer levels were restored, however the MFI was
slightly decreased compared to SHGAL and SHGI7AL.
Overall, the results show that the addition of accessory cis-
regulatory elements can improve gene expression in a cell-
type specific manner using a retroviral vector.
The extensive studies on the β-globin LCR in lentiviral vec-
tors have demonstrated that by proper placement of opti-
mal-sized LCR elements, it is possible to obtain a high
level of globin expression in a significant percentage of
erythroid cells in mice at an average vector copy number
of 1-2 [18]. Thus, gene therapy vectors are reaching a level
of sophistication that will allow clinical trials for sickle
cell anemia and β-thalassemia. By incorporation of the
ADA LCR into retroviral vectors, we have demonstrated
that T-cell-specific gene expression can be obtained in
vitro, suggesting that similar effects may be achieved in
vivo. The next step is to test these humanized ADA LCR-
containing vectors in primary cells, such as bone marrow
cells and various populations of stem cells, followed by
the transplantation of these transduced primary cells into
a mouse model. We believe that these vectors have the
potential to provide a safer and more effective treatment
option for genetic immunodeficiencies.
Conclusion
We have developed a series of fully humanized vector con-
structs containing several ADA regulatory elements. Vec-
tor SHGI7AL, which contains the human polyadenylation
growth hormone, intron 7 from the human ADA gene, the
ADA promoter and the ADA LCR, proved to show the
highest level of expression compared with the other vec-
tors. Even though the titer for this vector is not as high as
some of the other vectors, this can be overcome by titer
concentrations.
Vectors capable of authentic gene-specific regulation may
prove to be a safer and more effective alternative to previ-
ous vectors for the treatment of ADA-SCID through more
regulated, higher levels of gene expression. Furthermore,
together with studies on the human β-globin LCR, the vec-
tor constructs presented herein shed light on the possibil-
ity of generating a global model construct for the creation
of retroviral vectors capable of cell-specific expression for
the treatment of various genetic diseases.
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